U.S. FDA Orders Dainippon Sumitomo Unit To Lower Lunesta Dosage
This article was originally published in PharmAsia News
The U.S. FDA ordered Dainippon Sumitomo Pharma's U.S. subsidiary to halve the recommended dosage of its Lunesta (eszopiclone) sleeping pill and to change its label to reflect that.
You may also be interested in...
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.
Washington State Sen. Patty Murray said at a 4 June health panel hearing that having USPHS Admiral Brett Giroir step down as the nation’s COVID-19 “Testing Czar” is a bad move, but HHS disagrees.
Pink Sheet Podcast: Merck’s Frazier Speaks Out, US FDA’s Hahn On Decisions, Operation Warp Speed, Worries About User Fee Goal Delays
Pink Sheet reporters and editor discuss Merck CEO Ken Frazier’s thoughts on racial inequity, FDA Commissioner’s explanation of coronavirus decision-making and Operation Warp Speed changes, and consider fears about the potential for user fee goal delays.